Retension Pharmaceuticals, Inc. - Common Stock (RTSN)

About Retension Pharmaceuticals, Inc. - Common Stock (RTSN)

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.

Retension Pharmaceuticals, Inc. - Common Stock News